ADVANTAGES AND NOVELTY OF CLINICAL APPLICATION OF THE TRIPLE COMBINATION FOR ARTERIAL HYPERTENSION WITH DYSLIPIDEMIA: ACE INHIBITOR PERINDOPRIL WITH ROSUVASTATIN AND INDAPAMIDE

Aim. To assess efficacy and safety of double combinations (angiotensine converting enzyme inhibitor (ACEi) + indapamide) and triple combinations (ACEi + statin + indapamide) in arterial hypertnesion (AH) patients with dyslipidemia (DL).

Material and methods. The study is based on the data analysis obtained during investigation and treatment of 75 patients at the age 40-65 y.o. with AH of I-II grades and high risk with DL (total cholesterol more 4,5 mM/L, and/or low density lipoproteides more than 2,5 mM/L).

Results. During the study, additional properties of statins are shown, if added to standard bi-component hypotensive treatment by ACEi + indapamide, in patients with high cardiovascular risk (CVR). There is improvement of hypotensive and angioprotection effects. The advantages presented, as an additional angioprotection effect, endothelial function improvement and significance of clinical application of triple combination ACEi + rosuvastatin + indapamide in DL patients with AH of higher CVR.

Conclusion. The data shows that combination of ACEi + statin + indapamide is able to most effectively decrease damage caused by inflammation on vascular endothelium. In the analogic by strength hypotensive action, within combinational therapy, there is summation of angioprotection effects of both drugs. Synergistic angioprotection action of combination therapy makes it to recommend triplecomponent combination of ACEi + statin + indapamide for broader implementation in AH of I-II grades patients and DL of higher CVR as a combination of the drugs of choice showing pathogenetic mechanisms of correction of arterial pressure, as metabolic disorders, and resulting in organoprotective effect of treatment. The main point of interest could be a fixed triple component combination of perindopril + rosuvastatin + indapamide.

1. WHO. Cardiovascular diseases (CVDs). Fact sheet. Updated May 2017

2. Chazova IE, Rogatova LG, Boytsov SA, Nebieridze DV. Diagnosis and treatment of hypertension. Diagnosis and treatment of hypertension. Guidelines on the treatment of arterial hypertension of Russian Medical Society on Arterial Hypertension and the AllRussian Scientific Society of Cardiology. Systemic hypertension. 2010; 3: 5-26. Russian (Чазова И.Е., Рогатова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Четвертый пересмотр. Системные гипертензии. 2010; 3: 5-26).

3. Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. JHum Hypertens. 2000; 14: 83-90.

4. Briasoulis A, Agarwal V, Valachis A. Antihypertensive Effects of Statins: A Meta-Analysis of Prospective Controlled Studies. The Journal of Clinical Hypertension. 2013; 5 (15): 310-20.

5. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003; 23: 729-36.

6. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). ArchInternMed 2006; 166 (20): 2191-201.

7. Ermolaeva AS. Clinic-pharmacological analysis of pharmacodynamics effects of ACE inhibitors and HMG-COA reductase inhibitors in patients with arterial hypertension and dyslipidemia: specialty 14.03.06 Pharmacology, clinical pharmacology: dissertation for the applicant of PhD in Medical sciences. (First Moscow State Medical University named after IM Sechenov). Moscow, 2015. p. 139. Russian (Ермолаева А.С. Клиникофармакологический анализ фармакодинамических эффектов ингибиторов АПФ и ингибиторов ГМГ-КОА-редуктазы у больных с артериальной гипертонией и дислипидемией: специальность 14.03.06 Фармакология, клиническая фармакология: дис. на соиск. учен.степ. канд. мед. Наук.; (Первый Моск. гос. мед. ун-т им. И.М. Сеченова). Москва, 2015. c. 139).

8. Petrosyan KR, at al. Change in the vasoregulatory function of the endothelium in smokers in the age range. Collection of articles of the scientific-practical conference dedicated to the 70th anniversary of the city clinical hospital № 81. M., 2007. p. 369-74. Russian (Петросян К.Р., и др. Изменение вазорегулирующей функции эндотелия у курящих мужчин в возрастном аспекте. Сборник статей научно-практической конференции, посвященной 70-летию городской клинической больницы № 81. М., 2007. c. 369-74).

9. Kukes VG, DA Sychev. Clinical pharmacology. Textbook.Moscow: GEOTAR-Media, 2015. p.1024. Russian (Кукес В.Г., Сычев Д.А. Клиническая фармакология. Учебник. М.: ГЭОТАР-Медиа, 2015. с.1024).

10. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentrerandomised controlled trial. Lancet. 2003 Apr 5; 361(9364): 1149-58.

11. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of co-morbidity hypertension and dyslipidemia and associated cardiovascular disease. AmJManagCare. 2004; 10: 92632.

12. Morozova TE. The use of perindopril in smokers. What additionally does the drug help? Consilium Medicum 2013; 1: 56-60. Russian (Морозова Т.Е. Применение периндоприла у курящих пациентов. Чем дополнительно помогает препарат? Consilium Medicum. 2013; 1: 56-60).

13. Semenkin AA, Novikov AI, Nechaeva GI, at all. Endothelial and metabolic effects of perindopril in patients with essential hypertension. Cardiology. 2014; 7. Russian (Семенкин А.А., Новиков А.И., Нечаева Г.И., и др. Эндотелиальные и метаболические эффекты периндоприла у больных эссенциальной гипертензией. Кардиология, 2014: 7).

14. Jones PH, Hunninghake DB, Ferdinand KC, et al. Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. ClinTher. 2004 Sep; 26(9): 1388-99.

15. Ballantyne СМ, Bertolami M, Hemandez Carcia HR, et al. Achieving LDL cholesterol, non–HDL cholesterol, and apolipoprotein B target levels in high–risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY( MERCURY II). Am Heart J 2006; 151: 975. e1-e9.